Rosuvastatin Does Not Affect Fasting Glucose, Insulin Resistance, or Adiponectin in Patients with Mild to Moderate Hypertension
- Author:
Weon KIM
1
;
Myong Joo HONG
;
Jong Shin WOO
;
Won Yu KANG
;
Sun Ho HWANG
;
Wan KIM
Author Information
- Publication Type:Original Article
- Keywords: Hydroxymethylglutaryl-CoA reductase inhibitors; Insulin resistance; Adiponectin; Blood glucose
- MeSH: Adiponectin; Blood Glucose; Blood Pressure; Cholesterol; Fasting; Fluorobenzenes; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insulin; Insulin Resistance; Lipoproteins; Plasma; Prospective Studies; Pyrimidines; Single-Blind Method; Sulfonamides; Rosuvastatin Calcium
- From:Chonnam Medical Journal 2013;49(1):31-37
- CountryRepublic of Korea
- Language:English
- Abstract: The effects of statins on insulin resistance and new-onset diabetes are unclear. The purpose of this study was to evaluate the effects of rosuvastatin on insulin resistance and adiponectin in patients with mild to moderate hypertension. In a randomized, prospective, single-blind study, 53 hypertensive patients were randomly assigned to the control group (n=26) or the rosuvastatin (20 mg once daily) group (n=27) during an 8-week treatment period. Both groups showed significant improvements in systolic blood pressure and flow-mediated dilation (FMD) after 8 weeks of treatment. Rosuvastatin treatment improved total cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglyceride levels. The control and rosuvastatin treatment groups did not differ significantly in the change in HbA1c (3.0+/-10.1% vs. -1.3+/-12.7%; p=0.33), fasting glucose (-1.3+/-18.0% vs. 2.5+/-24.1%; p=0.69), or fasting insulin levels (5.2+/-70.5% vs. 22.6+/-133.2%; p=0.27) from baseline. Furthermore, the control and rosuvastatin treatment groups did not differ significantly in the change in the QUICKI insulin sensitivity index (mean change, 2.2+/-11.6% vs. 3.6+/-11.9%; p=0.64) or the HOMA index (11.6+/-94.9% vs. 32.4+/-176.7%; p=0.44). The plasma adiponectin level increased significantly in the rosuvastatin treatment group (p=0.046), but did not differ significantly from that in the control group (mean change, 23.2+/-28.4% vs. 23.1+/-27.6%; p=0.36). Eight weeks of rosuvastatin (20 mg) therapy resulted in no significant improvement or deterioration in fasting glucose levels, insulin resistance, or adiponectin levels in patients with mild to moderate hypertension.
